One of the most recent yet exciting areas of discovery research centers around targeting chromatin modifying proteins, particularly those responsible for the recognition of the histone code written in acetyl and methyl marks. With several clinical trials underway, and countless discovery programs initiated, particular interest has been given to targeting the bromodomain family of proteins across a diverse range of therapeutic indications. Advances in probe development allows for individual and polypharmacological targeting of BET and non-BET proteins, thus given rise to inhibitors modulating various disease pathways, creating novel phenotypic output, and providing a better understanding as to the individual roles of chromatin-associated proteins in human physiology and disease.
Cambridge Healthtech Institute's Third Annual Targeting Epigenetic Readers and Chromatin Remodelers meeting will once again unite academic and industry researchers for the development of chemical probes to further our understanding of the therapeutic opportunities associated with targeting reader domains and chromatin remodelers.
Who should attend: Executives, Directors, Managers, Researchers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oncology Drug Discovery, Research and Development, Molecular/Cell Biology, Biochemistry, Chemical Genomics/Biology, Structural Biology, Medicinal Chemistry, Pharmacology and Synthetic Chemistry.
Topics will include, but are not limited to:
- Target Identification and Validation
- Targeting Chromatin Remodelers, BET and Non-BET bromodomains, PhD, Tudor, Chromo, PWWP and MBT domains
- Novel Reader Targets with Therapeutic Implications in Cancer
- Selective Inhibition of Readers/Remodelers and Cellular Response
- Addressing Undesired Consequences of Inhibition
- Discovery to Lead
- Structural Characterization of Reader Domains and Remodeler Subunits
- High-Throughput Profiling and Screening for Inhibitors
- Virtual Screening
- Phenotypic Screening
- Fragment/Structure-Based Design
- Protein-Protein Interaction Strategies
- Development of High-Quality Chemical Probes/Scaffolds
- Discovery of Novel BET and Non-BET inhibitors
- Lead Optimization
- Dual Inhibitors
- Pre-Clinical and Clinical Development
- Updates on BET Bromodomain Programs in Preclinical and Clinical Stages
- Disease Relevant Pre-Clinical Models and Biomarkers
If you are interested in speaking, click here to submit a speaking proposal.
The deadline for submission is March 11, 2015.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Cambridge Healthtech Institute
T: (+1) 781-972-5454
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483